139 related articles for article (PubMed ID: 11051280)
1. T-cell activation and differentiation are regulated by TNF during murine DBA/2-->B6D2F1 intestinal graft-versus-host disease.
Brown GR; Thiele DL
J Clin Immunol; 2000 Sep; 20(5):379-88. PubMed ID: 11051280
[TBL] [Abstract][Full Text] [Related]
2. Tumor necrosis factor inhibitor ameliorates murine intestinal graft-versus-host disease.
Brown GR; Lindberg G; Meddings J; Silva M; Beutler B; Thiele D
Gastroenterology; 1999 Mar; 116(3):593-601. PubMed ID: 10029618
[TBL] [Abstract][Full Text] [Related]
3. TNF enhances CD4+ T cell alloproliferation, IFN-gamma responses, and intestinal graft-versus-host disease by IL-12-independent mechanisms.
Brown GR; Lee EL; Thiele DL
J Immunol; 2003 May; 170(10):5082-8. PubMed ID: 12734353
[TBL] [Abstract][Full Text] [Related]
4. TNF-TNFR2 interactions are critical for the development of intestinal graft-versus-host disease in MHC class II-disparate (C57BL/6J-->C57BL/6J x bm12)F1 mice.
Brown GR; Lee E; Thiele DL
J Immunol; 2002 Mar; 168(6):3065-71. PubMed ID: 11884480
[TBL] [Abstract][Full Text] [Related]
5. Intestinal graft-versus-host disease is initiated by donor T cells distinct from classic cytotoxic T lymphocytes.
Thiele DL; Eigenbrodt ML; Bryde SE; Eigenbrodt EH; Lipsky PE
J Clin Invest; 1989 Dec; 84(6):1947-56. PubMed ID: 2531761
[TBL] [Abstract][Full Text] [Related]
6. Butyric acid derivative induces allospecific T cell anergy and prevents graft-versus-host disease.
Gilbert KM; Boger S; Fifer EK
Immunopharmacol Immunotoxicol; 2003 Feb; 25(1):13-27. PubMed ID: 12675196
[TBL] [Abstract][Full Text] [Related]
7. Osteopontin attenuates acute gastrointestinal graft-versus-host disease by preventing apoptosis of intestinal epithelial cells.
Kawakami K; Minami N; Matsuura M; Iida T; Toyonaga T; Nagaishi K; Arimura Y; Fujimiya M; Uede T; Nakase H
Biochem Biophys Res Commun; 2017 Apr; 485(2):468-475. PubMed ID: 28192120
[TBL] [Abstract][Full Text] [Related]
8. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
Drobyski WR; Majewski D; Hanson G
Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
[TBL] [Abstract][Full Text] [Related]
9. The role of TNF in hepatic histopathological manifestations and hepatic CD8+ T cell alloresponses in murine MHC class I disparate GVHD.
El-Hayek JM; Rogers TE; Brown GR
J Leukoc Biol; 2005 Oct; 78(4):1001-7. PubMed ID: 16081594
[TBL] [Abstract][Full Text] [Related]
10. Phenotypic analysis of donor cells infiltrating the small intestinal epithelium and spleen during graft-versus-host disease.
Schattenfroh NC; Hoffman RA; McCarthy SA; Simmons RL
Transplantation; 1995 Jan; 59(2):268-73. PubMed ID: 7839451
[TBL] [Abstract][Full Text] [Related]
11. Triggered human mucosal T cells release tumour necrosis factor-alpha and interferon-gamma which kill human colonic epithelial cells.
Deem RL; Shanahan F; Targan SR
Clin Exp Immunol; 1991 Jan; 83(1):79-84. PubMed ID: 1899066
[TBL] [Abstract][Full Text] [Related]
12. Unexpected role of TNF-alpha in graft versus host reaction (GVHR): donor-derived TNF-alpha suppresses GVHR via inhibition of IFN-gamma-dependent donor type-1 immunity.
Yamamoto S; Tsuji T; Matsuzaki J; Zhange Y; Chamoto K; Kosaka A; Togashi Y; Sekikawa K; Sawada K; Takeshima T; Koike T; Nishimura T
Int Immunol; 2004 Jun; 16(6):811-7. PubMed ID: 15126416
[TBL] [Abstract][Full Text] [Related]
13. Donor CD8 T cell activation is critical for greater renal disease severity in female chronic graft-vs.-host mice and is associated with increased splenic ICOS(hi) host CD4 T cells and IL-21 expression.
Foster AD; Haas M; Puliaeva I; Soloviova K; Puliaev R; Via CS
Clin Immunol; 2010 Jul; 136(1):61-73. PubMed ID: 20451460
[TBL] [Abstract][Full Text] [Related]
14. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
Li JM; Waller EK
Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
[TBL] [Abstract][Full Text] [Related]
15. Role of mast cells in early epithelial target cell injury in experimental acute graft-versus-host disease.
Murphy GF; Sueki H; Teuscher C; Whitaker D; Korngold R
J Invest Dermatol; 1994 Apr; 102(4):451-61. PubMed ID: 7908682
[TBL] [Abstract][Full Text] [Related]
16. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.
Teshima T; Hill GR; Pan L; Brinson YS; van den Brink MR; Cooke KR; Ferrara JL
J Clin Invest; 1999 Aug; 104(3):317-25. PubMed ID: 10430613
[TBL] [Abstract][Full Text] [Related]
17. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment.
Drobyski WR; Majewski D; Ozker K; Hanson G
J Immunol; 1998 Sep; 161(5):2610-9. PubMed ID: 9725263
[TBL] [Abstract][Full Text] [Related]
18. Donor-derived IL-15 is critical for acute allogeneic graft-versus-host disease.
Blaser BW; Roychowdhury S; Kim DJ; Schwind NR; Bhatt D; Yuan W; Kusewitt DF; Ferketich AK; Caligiuri MA; Guimond M
Blood; 2005 Jan; 105(2):894-901. PubMed ID: 15374888
[TBL] [Abstract][Full Text] [Related]
19. Differential cytokine expression in acute and chronic murine graft-versus-host-disease.
Allen RD; Staley TA; Sidman CL
Eur J Immunol; 1993 Feb; 23(2):333-7. PubMed ID: 8436168
[TBL] [Abstract][Full Text] [Related]
20. Fas-deficient lpr mice are more susceptible to graft-versus-host disease.
van Den Brink MR; Moore E; Horndasch KJ; Crawford JM; Hoffman J; Murphy GF; Burakoff SJ
J Immunol; 2000 Jan; 164(1):469-80. PubMed ID: 10605044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
